Novo-Nordisk's stock surged 5.3% in pre-market trading on Wednesday, as investors braced for the Danish drugmaker's highly anticipated quarterly financial results. The pharmaceutical giant's GLP-1 drugs, including the weight-loss medication Wegovy and the Type 2 diabetes drug Ozempic, have been the subject of intense investor scrutiny and high hopes for blockbuster sales growth.
Despite recent setbacks, such as disappointing trial data for their next-generation weight-loss drug CagriSema and concerns about competition from rival drugmakers like Eli Lilly, analysts are expecting robust sales numbers for Wegovy and Ozempic in the fourth quarter. According to FactSet estimates, Wegovy sales are projected to reach 20 billion Danish Krone (approximately $2.8 billion), while Ozempic sales are expected to hit 33 billion Danish Krone (around $4.6 billion).
Moreover, investors are eagerly awaiting updates from Novo-Nordisk on their efforts to alleviate the supply constraints that have plagued these highly sought-after GLP-1 drugs. With an $11 billion deal struck in December to ramp up production, the company aims to address the global shortage and meet the surging demand for these groundbreaking medications.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。